28657-75-2

Basic information

• Product Name: 6-Amino-3,4-methylenedioxyacetophenone
• Synonyms: 2'-AMINO-4',5'-METHYLENEDIOXYACETOPHENONE;2-AMINO-4,5-METHYLENEDIOXYACETOPHENONE;6'-AMINO-3',4'-(METHYLENEDIOXY)ACETOPHENONE;6-AMINO-3,4-METHYLENEDIOXYACETOPHENONE;6-AMINOACETOPIPERONE;LABOTEST-BB LT00080791;TIMTEC-BB SBB007568;1-(6-amino-1,3-benzodioxol-5-yl)ethan-1-one
• CAS NO: 28657-75-2
• Molecular Formula: C9H9NO3
• Molecular Weight: 179.17
• EINECS: 249-131-7
• Product Categories: Aromatic Acetophenones & Derivatives (substituted);Benzene series
• Mol File: 28657-75-2.mol
• Article Data: 17

Chemical Properties

• Melting Point: 168-171 °C
• Boiling Point: 158 °C (30 mmHg)
• Flash Point: 218.6 °C
• Appearance: Brown/Fine Granular Crystalline Powder
• Density: 1.2822 (rough estimate)
• Vapor Pressure: 1.22E-05mmHg at 25°C
• Refractive Index: 1.5600 (estimate)
• Solubility: soluble in Dimethylformamide
• PKA: 2.48±0.20(Predicted)
• CAS DataBase Reference: 6-Amino-3,4-methylenedioxyacetophenone(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Amino-3,4-methylenedioxyacetophenone(28657-75-2)
• EPA Substance Registry System: 6-Amino-3,4-methylenedioxyacetophenone(28657-75-2)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 36/37/38-22
• Safety Statements: 37/39-26-36
• Hazardous Substances Data: 28657-75-2(Hazardous Substances Data)

Usage

Chemical Properties

brown fine granular crystalline powder

InChI:InChI=1/C9H9NO3/c1-5(11)6-2-8-9(3-7(6)10)13-4-12-8/h2-3H,4,10H2,1H3

Upstream product

• 1809-10-5 3-bromopentane 
• 98-88-4 benzoyl chloride 
• 187164-87-0 5-amino-6-cyanobenzo<1,3>dioxale 
• 75-16-1 methylmagnesium bromide 
• 460994-52-9 N-(6-acetylbenzo[d][1,3]dioxol-5-yl)-4-methylbenzenesulfonamide 
• 58277-23-9 7-ethoxycarbonylamino-8-methyl-[1,3]dioxolo[4,5-g]quinazolinium betaine 
• 109-73-9 N-butylamine 
• 56136-84-6 methyl 3,4-(methylenedioxy)-6-nitrophenyl ketone 
• 6343-27-7 1-benzoylpyrrolidine-2,5-dione 
• 109-66-0 pentane 
• 6668-31-1 N-Formyl-2-ethyl-1-phenylbutylamin 
• 98-86-2 acetophenone 
• 100-52-7 benzaldehyde 
• 616-20-6 3-chloropentane 

Downstream Products

• 85591-08-8 (8-Methyl-[1,3]dioxolo[4,5-g]quinazolin-6-ylmethyl)-phenyl-amine 
• 85590-95-0 2'-acetyl-2-anilino-4',5'-methylenedioxyacetanilide 
• 85590-96-1 2'-acetyl-2-benzylamino-4',5'-methylenedioxyacetanilide 
• 85591-13-5 ethyl N-(4-methyl-6,7-methylenedioxy-2-quinazolinylmethyl)-N-phenylcarbamate 
• 85590-98-3 2-{[2-(6-Acetylamino-benzo[1,3]dioxol-5-yl)-2-oxo-ethyl]-benzyl-amino}-N-(6-acetyl-benzo[1,3]dioxol-5-yl)-acetamide 
• 158598-60-8 3'-fluoro-6,7-(methylenedioxy)-2-phenyl-4-quinolone 
• 1431472-16-0 benzyl 6,8-dimethyl[1,3]dioxolo[4,5-g]quinoline-7-carboxylate 
• 1204312-43-5 6-phenyl-8H-[1,3]dioxolo[4',5':4,5]benzo[1,2-d][1,3]oxazin-8-one 
• 828275-16-7 C₁₈H₁₇NO₃ 
• 75403-98-4 C₁₉H₁₈O₆ 
• 421766-44-1 1-(6-amino-1,3-benzodioxol-5-yl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one 
• 178983-58-9 N-(6-Acetyl-benzo[1,3]dioxol-5-yl)-3-nitro-benzamide 

Relevant articles and documents

Direct formation of secondary and tertiary alkylzinc bromides

The direct formation of secondary and tertiary alkylzinc bromides can be accomplished under mild conditions from the direct oxidative addition of Rieke zinc to secondary and tertiary alkyl bromides including remote functionalized halides.

MATTER OF COMPOSITION, SYNTHESIS, FORMULATION AND APPLICATION OF FL118 PLATFORM POSITIONS 7 AND 9-DERIVED ANALOGUES FOR TREATMENT OF HUMAN DISEASE

Described herein, are the chemical synthesis, matter of compositions, formulation, function, methods and uses of the FL118 platform Positions 7 and/or 9-derived analogues for treating cancer or other human diseases. Compounds derived from chemical modifications of the FL118 platform are employed alone or in combination with other anti-cancer agents to preclude, eliminate or reverse cancer phenotypes. This invention intends to realize unique personalized cancer treatment (personalized precision medicine) through application of a series of structural relevant individual FL118 platform-derived analogues, which target multiple cellular human disease-relevant proteins and their signaling pathways.

Camptothecin derivative and preparation method and application thereof

The invention relates to a compound with a structure shown in a formula (I), a stereoisomer of the compound and a pharmaceutically acceptable salt form of the compound, and further relates to a preparation method of the compound, a pharmaceutical composition containing therapeutically effective dose of the compound, and application of the pharmaceutical composition in the preparation for the prevention and/or treatment of cancer. The compound is a camptothecin derivative with a novel structure with 10 site and 11 site of a stem nucleus introduced with methylene dioxy groups and 7-site introduced with different substituted groups. The raw materials of the preparation method can be obtained easily, a synthetic method is simple, a purification method is simple and fast, the compound has excellent cytotoxic activity in vitro and excellent antitumor effect in vivo, and the compound has broad medicinal prospects.(Please see the specification for the formula).

Palladium catalyzed decarboxylative acylation of arylboronic acid with ethyl cyanoacetate as a new acylating agent: Synthesis of alkyl aryl ketones

Palladium catalyzed acylation of arylboronic acid containing various functional groups was performed efficiently by ethyl cyanoacetate/substituted ethyl cyanoacetate as the acylating agent in aqueous triflic acid medium. The alkyl aryl ketones were obtained in good to excellent yields, first by addition of arylboronic acid to the nitrile group of ethyl cyanoacetate and their derivatives, followed by in situ decarboxylation of the resulting β-ketoester.